Sector Expert: Brian Klein

Stifel



Recent Quotes

"INO confirms its VGX-3100 Phase 2 data readout is coming this summer."

— Brian Klein, Stifel (6/6/14)
more >

"ONC's Reolysin trial showed compelling tumor response improvement."

— Brian Klein, Stifel (12/13/12)
more >

"We anticipate ONC's trials will demonstrate compelling improvements on disease progression."

— Brian Klein, Stifel (11/9/12)
more >

"The reporting setback in ONC's head and neck study should lead to more robust results."

— Brian Klein, Stifel (9/12/12)
more >

"We are initiating coverage of ONC with a Buy rating and adding it to the Stifel Nicolaus Select List."

— Brian Klein, Stifel (8/29/12)
more >

"CYCC remains undervalued, with a compelling oncology asset and large commercial opportunity."

— Brian Klein, Lazard Capital Markets (3/30/12)
more >



Due to permission requirements, not all quotes are shown.